从中医药治疗胃食管反流病的优势环节解读《中药新药用于胃食管反流病的临床疗效评价指导原则》

王凤云; 吕咪

doi:10.3969/j.issn.1671-038X.2023.07.02

从中医药治疗胃食管反流病的优势环节解读《中药新药用于胃食管反流病的临床疗效评价指导原则》

王凤云^1, ,,
吕咪^1,2

- 1.
  中国中医科学院西苑医院消化科(北京，100091)
- 2.
  中国中医科学院研究生院
基金项目:
中国中医科学院科技创新工程(No：CI2021A01001)；国家自然科学基金项目(No：82205104, No：82004355)；中国中医科学院优秀青年科技创新人才培养专项(No：ZZ14-YQ-005)

详细信息

通讯作者: 王凤云，E-mail：wfy811@163.com

中图分类号: R473.5

收稿日期: 2023-05-29

刊出日期: 2023-07-15

Interpreting Guiding principles for the clinical efficacy evaluation of new Traditional Chinese Medicine drugs used in gastroesophageal reflux disease from the strengths of Traditional Chinese Medicine in the treatment of gastroesophageal reflux disease

WANG Fengyun^1, ,,
LV Mi^1,2

- 1.
  Department of Gastroenterology, Xiyuan Hospital, China Academy of Traditional Chinese Medical Sciences, Beijing, 100091, China
- 2.
  Graduate School of China Academy of Chinese Medical Sciences

More Information

Corresponding author: WANG Fengyun, E-mail: wfy811@163.com

Received Date: 29 May 2023

Publish Date: 15 July 2023

摘要

摘要: 胃食管反流病(gastroesophageal reflux disease，GERD)是上消化道最常见的难治病之一，以症状繁杂、容易反复、严重影响患者生活质量为特征。中药复方对GERD典型症状、不典型症状、食管外症状及难治性GERD的症状改善及远期疗效均有较好作用，在协同西药提高疗效、增强安全性和减少复发方面优势突出。本文在中医药理论、人用经验和临床试验相结合的中药注册审评证据体系下，结合中医药治疗GERD的优势环节对《中药新药用于胃食管反流病的临床疗效评价指导原则》的编写要点进行提炼、解读，为GERD的中药新药研发方案设计和实施等提供更好的指导。
- 胃食管反流病 /
- 指导原则 /
- 优势环节 /
- “三结合”体系 /
- 编写要点
Abstract: Gastroesophageal reflux disease(GERD) is one of the most common refractory diseases of the upper gastrointestinal tract, which is characterized by complicated symptoms, easy recurrence, and seriously affecting the quality of life of patients. Traditional Chinese Medicine(TCM) compound has a good effect on the improvement of typical symptoms, atypical symptoms, extra-esophageal symptoms and refractory GERD symptoms and long-term efficacy, and has outstanding advantages in improving efficacy, enhancing safety and reducing recurrence when combined with western medicine. Under the TCM registration and review evidence system, which combines TCM theory, human experience and clinical trials, this paper aims to extract and interpret the key points of writing of Guiding principles for the clinical efficacy evaluation of new Traditional Chinese Medicine drugs used in gastroesophageal reflux disease combined with the advantages of TCM in the treatment of GERD, so as to provide better guidance for the design and implementation of TCM new drug research and development for GERD.
- gastroesophageal reflux disease /
- guiding principles /
- advantage part /
- "Three-combination" system /
- key points of writing

HTML全文

参考文献(16)

[1]	周金池, 赵曙光, 王新, 等. 中国部分地区基于社区人群胃食管反流病患病率Meta分析[J]. 胃肠病学和肝病学杂志, 2020, 29(9): 1012-1020. https://www.cnki.com.cn/Article/CJFDTOTAL-WCBX202009013.htm
[2]	Rettura F, Bronzini F, Campigotto M, et al. Refractory Gastroesophageal Reflux Disease: A Management Update[J]. Front Med(Lausanne), 2021, 8: 765061.
[3]	Lee KJ. Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease[J]. Korean J Gastroenterol, 2015, 66(2): 70-74. doi: 10.4166/kjg.2015.66.2.70
[4]	Savarino V, Marabotto E, Zentilin P, et al. Esophageal reflux hypersensitivity: Non-GERD or still GERD?[J]. Dig Liver Dis, 2020, 52(12): 1413-1420. doi: 10.1016/j.dld.2020.10.003
[5]	国家药监局药审中心关于发布《中药新药用于慢性胃炎的临床疗效评价技术指导原则(试行)》《中药新药用于胃食管反流病的临床疗效评价技术指导原则(试行)》的通告(2022年第47号)[J]. 中国临床药理学杂志, 2023, 39(4): 512-512.
[6]	Kim GH. Proton Pump Inhibitor-Related Gastric Mucosal Changes[J]. Gut Liver, 2021, 15(5): 646-652. doi: 10.5009/gnl20036
[7]	Seo SI, Park CH, You SC, et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea[J]. Gut, 2021, 70(11): 2066-2075. doi: 10.1136/gutjnl-2020-323845
[8]	Maes ML, Fixen DR, Linnebur SA. Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence[J]. Ther Adv Drug Saf, 2017, 8(9): 273-297. doi: 10.1177/2042098617715381
[9]	Eusebi LH, Rabitti S, Artesiani ML, et al. Proton pump inhibitors: Risks of long-term use[J]. J Gastroenterol Hepatol, 2017, 32(7): 1295-1302. doi: 10.1111/jgh.13737
[10]	李保双, 张丽颖, 彭珍婷, 等. 通降颗粒干预非糜烂性反流病肝胃不和证疗效观察[J]. 中国中西医结合杂志, 2013, 33(7): 915-919. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201307016.htm
[11]	刘礼剑, 杨成宁, 陈广文, 等. 调中化湿汤治疗难治性胃食管反流病的临床疗效观察[J]. 中国中西医结合消化杂志, 2019, 27(12): 910-915. http://zxpw.cbpt.cnki.net/WKD2/WebPublication/paperDigest.aspx?paperID=348d9983-af0b-4bd3-9e4f-37faa5d41a06
[12]	Zhang J, Che H, Zhang B, et al. JianpiQinghua granule reduced PPI dosage in patients with nonerosive reflux disease: A multicenter, randomized, double-blind, double-dummy, noninferiority study[J]. Phytomedicine, 2021, 88: 153584. doi: 10.1016/j.phymed.2021.153584
[13]	李秀娟, 张素, 张伟伟, 等. 中医药预防胃食管反流病复发随机对照试验的系统评价[J]. 福建中医药, 2010, 41(6): 5-9. https://www.cnki.com.cn/Article/CJFDTOTAL-FJZY201006003.htm
[14]	舒欣, 张薇. 中药联合质子泵抑制剂治疗肝胃郁热型反流性食管炎的系统分析[J]. 光明中医, 2023, 38(1): 17-22.
[15]	中共中央国务院关于促进中医药传承创新发展的意见[N]. 人民日报, 2019-10-27(001).
[16]	Gralnek IM, Dulai GS, Fennerty MB, et al. Esomeprazole versus other proton pump inhibitors in erosive esophagitis: a meta-analysis of randomized clinical trials[J]. Clin Gastroenterol Hepatol, 2006, 4(12): 1452-1458.